PACIRA BIOSCIENCES INC (PCRX) Stock Analyst Ratings
USA - NASDAQ:PCRX - US6951271005 - Common Stock
22.05 USD
+0.95 (+4.5%)
22.05 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 77% to PCRX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 38.15. This target is 73.01% above the current price.
PCRX was analyzed by 13 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about PCRX.
In the previous month the buy percentage consensus was at a similar level.
PCRX was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-07 | Truist Securities | Maintains | Buy -> Buy |
| 2025-05-09 | Needham | Maintains | Buy -> Buy |
| 2025-04-08 | Needham | Reiterate | Buy -> Buy |
| 2025-04-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-28 | Needham | Maintains | Buy -> Buy |
| 2025-02-28 | Barclays | Maintains | Overweight -> Overweight |
| 2025-02-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-30 | Truist Securities | Upgrade | Sell -> Hold |
| 2025-01-14 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2025-01-13 | Needham | Maintains | Buy -> Buy |
| 2024-12-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-11-08 | Needham | Reiterate | Buy -> Buy |
| 2024-11-07 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-10-04 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-09-24 | Jefferies | Maintains | Buy -> Buy |
| 2024-08-13 | Truist Securities | Downgrade | Buy -> Sell |
| 2024-08-12 | Needham | Maintains | Buy -> Buy |
| 2024-08-12 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2024-08-12 | JP Morgan | Downgrade | Overweight -> Underweight |
| 2024-08-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-07-31 | Needham | Reiterate | Buy -> Buy |
| 2024-07-31 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-07-31 | Raymond James | Maintains | Outperform -> Outperform |
| 2024-07-25 | Truist Securities | Maintains | Buy -> Buy |
| 2024-07-03 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2024-07-03 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-07-02 | Needham | Reiterate | Buy -> Buy |
| 2024-07-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-08 | Needham | Maintains | Buy -> Buy |
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the average price target for PACIRA BIOSCIENCES INC (PCRX) stock?
13 analysts have analysed PCRX and the average price target is 38.15 USD. This implies a price increase of 73.01% is expected in the next year compared to the current price of 22.05.
What is the consensus rating for PACIRA BIOSCIENCES INC (PCRX) stock?
The consensus rating for PACIRA BIOSCIENCES INC (PCRX) is 76.9231 / 100 . This indicates that analysts generally have a positive outlook on the stock.